Memory-modulatory effects of centrally acting noradrenergic drugs: possible involvement of brain cholinergic mechanisms.
Post-training administration of the centrally acting muscarinic agonist oxotremorine (50.0 microgram/kg, ip) facilitated 48-hr retention, in mice, of a one-trial step-through inhibitory avoidance response. Oxotremorine-induced memory facilitation was not prevented by the simultaneous post-training administration of the central beta-adrenoceptor antagonist propranolol (2.0 mg/kg, ip). In contrast, post-training administration of atropine (0.5 mg/kg, ip), but not methylatropine (0.5 mg/kg, ip), completely prevented the facilitatory effects of the central beta-adrenoceptor agonist clenbuterol (30.0 micrograms/kg, ip) on retention. Low subeffective doses of clenbuterol (3.0 micrograms/kg, ip) and oxotremorine (6.25 or 12.5 micrograms/kg, ip) potentiated their effects and facilitated retention when given simultaneously immediately post-training. These results suggest that clenbuterol may induce memory facilitation through an increase of the release of acetylcholine in the brain. Post-training administration of a high dose of clenbuterol (1.0 mg/kg, ip) significantly impaired retention. Clenbuterol (1.0 mg/kg, ip)-induced impairment of retention was completely prevented by simultaneous post-training administration of oxotremorine (6.25, 12.5, or 50.0 micrograms/kg, ip). The centrally acting anticholinesterase physostigmine (21.5 or 68.0 micrograms/kg, ip) partially prevented clenbuterol-induced impairment of memory. The peripherally acting anticholinesterase neostigmine (68.0 micrograms/kg, ip) modified neither retention nor the amnestic effects of clenbuterol. Considered together, these findings are consistent with the view that brain muscarinic cholinergic mechanisms are involved in both the facilitatory and impairing effect of post-training clenbuterol on the modulation of memory storage.
Introini-Collison
I B
IB
Center for the Neurobiology of Learning and Memory, University of California, Irvine 92717.
Baratti
C M
CM
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001286:Atropine Derivatives / Q000494:pharmacology; D001362:Avoidance Learning / Q000187:drug effects*; D001921:Brain / Q000187:drug effects*; D002799:Cholinergic Fibers / Q000187:drug effects; D002976:Clenbuterol / Q000494:pharmacology; D008297:Male; D011939:Mental Recall / Q000187:drug effects*; D051379:Mice; D009388:Neostigmine / Q000494:pharmacology; D010095:Oxotremorine / Q000031:analogs & derivatives / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology; D010277:Parasympathomimetics / Q000494:pharmacology; D010830:Physostigmine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011930:Reaction Time / Q000187:drug effects; D011941:Receptors, Adrenergic / Q000187:drug effects*; D011976:Receptors, Muscarinic / Q000187:drug effects*; D012153:Retention, Psychology / Q000187:drug effects*
D001286:Atropine Derivatives; D010276:Parasympatholytics; D010277:Parasympathomimetics; D011941:Receptors, Adrenergic; D011976:Receptors, Muscarinic; C049425:oxotremorine sesquifumarate; D009388:Neostigmine; D010095:Oxotremorine; D001285:Atropine; C006649:methylatropine; D010830:Physostigmine; D011433:Propranolol; D002976:Clenbuterol